Business Context and Reporting Period
Bioceres Crop Solutions Corp. filed a Form 6-K for September 2021, reporting that its subsidiary, Rizobacter Argentina S.A., completed a public offering of Series VI corporate bonds in Argentina on September 3, 2021.
Bioceres is a global provider of crop productivity technologies, including seeds, microbial agricultural inputs, crop nutrition and protection products, and digital solutions supporting traceability and grower decisions.
Financing and Key Financial Metrics
| Tranche | Principal | Maturity | Annual nominal interest rate |
|---|---|---|---|
| Class A | US$12.7 million | March 2023 | 3.75% |
| Class B | US$3.4 million | September 2024 | 5.25% |
| Total | US$16.1 million | Various | Various |
Proceeds are intended for working capital and general corporate purposes, including extending debt maturities and reducing financing costs. The filing does not provide revenue, profit, cash flow, margin, total debt, cash balance, or liquidity metrics for the reporting period.
Material Changes Versus Prior Comparable Period
The filing reports the completion of the US$16.1 million bond offering but does not provide comparative operating or financial results. The transaction increases Rizobacter’s financing and is intended to improve the maturity profile and financing costs of its debt.
Guidance, Outlook, Risks, and Unusual Items
No quantitative financial guidance or operational outlook is provided. The filing contains customary forward-looking statement disclaimers and identifies risks including COVID-19 effects on the Company’s business, operations, liquidity, and financial results, as well as risks described in the Company’s SEC filings.
The bonds were not registered under the U.S. Securities Act and may be resold only pursuant to registration or an applicable exemption.
Investor Verification Points
- Verify the final bond terms, including issuance proceeds, covenants, security, and repayment obligations.
- Assess Rizobacter’s and Bioceres’ consolidated debt maturity profile after the offering.
- Confirm how proceeds were allocated between working capital, general corporate purposes, refinancing, and cost reduction.
- Review subsequent filings for the offering’s effect on interest expense, liquidity, leverage, and cash flow.
- Review current risk factors, including COVID-19 exposure and other risks referenced in the Company’s SEC filings.